South Canterbury's biotech adventure entangles BNZ
Hot Topic
EARNINGS
Receivers of a failed Allan Hubbard-led punt on curing cancer trying to recover funds for South Canterbury Finance are having to contend with caveats placed by BNZ.
The National Business Review broke the news in April of Allan Hubbard and South Canterbury’s tangled related-links to
Want to read more? It's easy.
Choose your best value subscription option
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
NZ$399.00 / yearly
Smartphone Only Annual Subscription
NZ$299.00 / yearly
Monthly Premium Online Subscription
NZ$49.95 / monthly
Smartphone Only Subscription
NZ$29.95 / monthly
Premium Group Membership 10 Users
NZ$385+GST / monthly
$38.5 per user - Pay by monthly credit card debitPremium Group Membership 20 Users
NZ$660+GST / monthly
$33 per user - Pay by monthly credit card debitPremium Group Membership 50 Users
NZ$1375+GST / monthly
$27.5 per user - Pay by monthly credit card debitPremium Group Membership 100 Users
NZ$2100+GST / monthly
$21 per user - Pay by monthly credit card debitYearly Premium Online Subscription + NBR Marketplace
NZ$499.00 / yearly
Already have an account? Login
Matt Nippert
Wed, 08 Jun 2011
Wed, 08 Jun 2011
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
South Canterbury's biotech adventure entangles BNZ
15100